hotspot -WSS

hotspot

author：hotspot 2025-09-06 09:10:18 - browse：8976

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Plastic surgeons increase patient psychiatric screenings

leisure time

Wikipedia

WSS

Vertex Pharmaceuticals may move headquarters in Boston

Eliminate the waiting period for sterilization covered by Medicaid

There's no autism epidemic. It's an autism diagnosis epidemic

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Scientists boost immune system in aging mice by making it youthful

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Wikipedia

hotspot

entertainment

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Merck, Vertex, and Viking updates

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Leading voice in opioid treatment defends methadone clinic system

Walensky prepares to leave CDC — and Congress — behind

Health AI adoption puts security, privacy startups on investors' radar

Walensky prepares to leave CDC — and Congress — behind

Donor acceptance rates hint at racial, gender bias in heart transplants: study

New air purifier tech could be key to improving indoor air quality

Donor acceptance rates hint at racial, gender bias in heart transplants: study

entertainment

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Stop the failed accountable care organization experiment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Future doctors should be trained to promote social change

leisure time

entertainment

Wikipedia

focus